{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:45:06Z","timestamp":1790203506829,"version":"4.1.0"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003970","name":"Isfahan University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003970","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.intimp.2020.106760","type":"journal-article","created":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T05:41:13Z","timestamp":1594014073000},"page":"106760","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["An update on antiviral antibody-based biopharmaceuticals"],"prefix":"10.1016","volume":"86","author":[{"given":"Shahrzad","family":"Ahangarzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Payandeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roghaye","family":"Arezumand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiana","family":"Shahzamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Yarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Alibakhshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2020.106760_b0005","doi-asserted-by":"crossref","unstructured":"C.O. Wilke, S.L. Sawyer, At the mercy of viruses, vol. 5, 2016.","DOI":"10.7554\/eLife.16758"},{"key":"10.1016\/j.intimp.2020.106760_b0010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/B978-0-12-803109-4.00004-0","article-title":"Methods to study viruses","author":"Payne","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.intimp.2020.106760_b0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-94-007-6552-8_1","article-title":"Introduction: the structural basis of virus function","volume":"68","author":"Mateu","year":"2013","journal-title":"Subcell. Biochem."},{"issue":"2","key":"10.1016\/j.intimp.2020.106760_b0020","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.coviro.2013.03.002","article-title":"Emerging viruses","volume":"3","author":"Lipkin","year":"2013","journal-title":"Curr. Opin. Virol."},{"issue":"1","key":"10.1016\/j.intimp.2020.106760_b0025","doi-asserted-by":"crossref","first-page":"e00042","DOI":"10.1128\/CMR.00042-18","article-title":"Practical guidance for clinical microbiology laboratories: viruses causing acute respiratory tract infections","volume":"32","author":"Charlton","year":"2018","journal-title":"Clin. Microbiol. Rev."},{"issue":"10","key":"10.1016\/j.intimp.2020.106760_b0030","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.tim.2015.07.005","article-title":"Antiviral monoclonal antibodies: can they be more than simple neutralizing agents?","volume":"23","author":"Pelegrin","year":"2015","journal-title":"Trends Microbiol."},{"issue":"21","key":"10.1016\/j.intimp.2020.106760_b0035","doi-asserted-by":"crossref","first-page":"9813","DOI":"10.1128\/JVI.74.21.9813-9817.2000","article-title":"Role of antibodies in controlling viral disease: lessons from experiments of nature and gene knockouts","volume":"74","author":"Sanna","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.intimp.2020.106760_b0040","doi-asserted-by":"crossref","DOI":"10.1038\/emi.2016.97","article-title":"Converting monoclonal antibody-based immunotherapies from passive to active: bringing immune complexes into play","volume":"5","author":"Lambour","year":"2016","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.intimp.2020.106760_b0045","doi-asserted-by":"crossref","first-page":"A132","DOI":"10.1016\/j.vaccine.2018.11.004","article-title":"Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: a review of the current status of the clinical development pipeline","volume":"37","author":"Sparrow","year":"2019","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.intimp.2020.106760_b0050","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/cid\/cix791","article-title":"Comparison of a novel human rabies monoclonal antibody to human rabies immunoglobulin for postexposure prophylaxis: a phase 2\/3, randomized, single-blind, noninferiority, controlled study","volume":"66","author":"Gogtay","year":"2018","journal-title":"Clin. Infect. Diseases: Offic. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.intimp.2020.106760_b0055","doi-asserted-by":"crossref","unstructured":"H. Kaplon, M. Muralidharan, Z. Schneider, J.M. Reichert, Antibodies to watch in 2020 2(1) (2020) 1703531.","DOI":"10.1080\/19420862.2019.1703531"},{"key":"10.1016\/j.intimp.2020.106760_b0060","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jconrel.2017.10.036","article-title":"Targeted cancer therapy through antibody fragments-decorated nanomedicines","volume":"268","author":"Alibakhshi","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.intimp.2020.106760_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.05.047","article-title":"Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies","author":"Wrapp","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2020.106760_b0070","doi-asserted-by":"crossref","first-page":"14158","DOI":"10.1038\/ncomms14158","article-title":"Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state","volume":"8","author":"Rossey","year":"2017","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.intimp.2020.106760_b0075","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.vaccine.2016.09.026","article-title":"Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection","volume":"35","author":"Mejias","year":"2017","journal-title":"Vaccine"},{"issue":"440","key":"10.1016\/j.intimp.2020.106760_b0080","article-title":"Diagnostic potential of recombinant scFv antibodies generated against hemagglutinin protein of influenza a virus","volume":"6","author":"Rajput","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2020.106760_b0085","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8724549","article-title":"Antibody-mediated therapy against HIV\/AIDS: Where are we standing now?","volume":"2018","author":"Awi","year":"2018","journal-title":"J. Pathogens"},{"issue":"1","key":"10.1016\/j.intimp.2020.106760_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12977-018-0455-9","article-title":"Antibody-mediated prevention and treatment of HIV-1 infection","volume":"15","author":"Gruell","year":"2018","journal-title":"Retrovirology"},{"issue":"1","key":"10.1016\/j.intimp.2020.106760_b0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-03335-4","article-title":"Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity","volume":"9","author":"Steinhardt","year":"2018","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.intimp.2020.106760_b0100","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1517\/14728222.2015.1010513","article-title":"HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth","volume":"19","author":"Acharya","year":"2015","journal-title":"Expert Opin. Therapeutic Targets"},{"key":"10.1016\/j.intimp.2020.106760_b0105","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/6743904","article-title":"Development of monoclonal antibodies against HIV-1 p24 protein and its application in colloidal gold immunochromatographic assay for HIV-1 detection","volume":"2016","author":"Ma","year":"2016","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.intimp.2020.106760_b0110","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.coviro.2018.04.002","article-title":"Viral envelope-specific antibodies in chronic hepatitis B virus infection","volume":"30","author":"Corti","year":"2018","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.intimp.2020.106760_b0115","doi-asserted-by":"crossref","first-page":"29391","DOI":"10.1038\/srep29391","article-title":"Efficient inhibition of hepatitis B virus infection by a preS1-binding peptide","volume":"6","author":"Ye","year":"2016","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2020.106760_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.09.002","article-title":"A human bi-specific antibody against Zika virus with high therapeutic potential","volume":"171","author":"Wang","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.intimp.2020.106760_b0125","doi-asserted-by":"crossref","first-page":"56","DOI":"10.4103\/ijp.IJP_115_20","article-title":"Drug targets for corona virus: a systematic review","volume":"52","author":"Prajapat","year":"2020","journal-title":"Indian J. Pharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2020.106760_b0130","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.micinf.2014.11.008","article-title":"Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections","volume":"17","author":"Ying","year":"2015","journal-title":"Microbes Infect."},{"key":"10.1016\/j.intimp.2020.106760_b0135","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jviromet.2018.03.012","article-title":"Comparative testing of HPV L1 protein monoclonal antibody panel for the detection of HPV in cervical exfoliated cells","volume":"257","author":"Wang","year":"2018","journal-title":"J. Virol. Methods"},{"issue":"4","key":"10.1016\/j.intimp.2020.106760_b0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095263","article-title":"Development of VHH antibodies against dengue virus type 2 NS1 and comparison with monoclonal antibodies for use in immunological diagnosis","volume":"9","author":"Fatima","year":"2014","journal-title":"PLoS ONE"},{"issue":"509","key":"10.1016\/j.intimp.2020.106760_b0145","article-title":"Development of monoclonal antibody and diagnostic test for middle east respiratory syndrome coronavirus using cell-free synthesized nucleocapsid antigen","volume":"7","author":"Yamaoka","year":"2016","journal-title":"Front. Microbiol."},{"issue":"2","key":"10.1016\/j.intimp.2020.106760_b0150","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1476-5381.2009.00190.x","article-title":"Therapeutic antibodies: successes, limitations and hopes for the future","volume":"157","author":"Chames","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.intimp.2020.106760_b0155","series-title":"Molecular engineering of antibodies for therapeutic and diagnostic purposes. MAbs","year":"2012"},{"issue":"5\u20136","key":"10.1016\/j.intimp.2020.106760_b0160","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.addr.2006.01.025","article-title":"Latest technologies for the enhancement of antibody affinity","volume":"58","author":"Wark","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.intimp.2020.106760_b0165","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.molcatb.2012.04.021","article-title":"Thermostability improvement of Orpinomyces sp. xylanase by directed evolution","volume":"81","author":"Trevizano","year":"2012","journal-title":"J. Mol. Catal. B Enzym."},{"key":"10.1016\/j.intimp.2020.106760_b0170","series-title":"Protein Chromatography","first-page":"87","article-title":"Phage display: a powerful technology for the generation of high specificity affinity reagents from alternative immune sources","author":"Finlay","year":"2011"},{"key":"10.1016\/j.intimp.2020.106760_b0175","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/bs.mie.2016.05.005","article-title":"Protein and antibody engineering by phage display","volume":"580","author":"Frei","year":"2016","journal-title":"Methods Enzymol."},{"issue":"3","key":"10.1016\/j.intimp.2020.106760_b0180","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nmeth1003","article-title":"Ribosome display: selecting and evolving proteins in vitro that specifically bind to a target","volume":"4","author":"Zahnd","year":"2007","journal-title":"Nat. Methods"},{"issue":"4","key":"10.1016\/j.intimp.2020.106760_b0185","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.drudis.2013.10.011","article-title":"mRNA display: from basic principles to macrocycle drug discovery","volume":"19","author":"Josephson","year":"2014","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.intimp.2020.106760_b0190","article-title":"Bioinformatics prediction and experimental validation of VH antibody fragment interacting with Neisseria meningitidis factor H binding protein","author":"Rafighdoust","year":"2020","journal-title":"Iranian J. Basic Med. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2020.106760_b0195","article-title":"Antibody engineering for the development of therapeutic antibodies","volume":"20","author":"Kim","year":"2005","journal-title":"Mole. Cells (Springer Science & Business Media BV)"},{"issue":"4","key":"10.1016\/j.intimp.2020.106760_b0200","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.coi.2008.06.012","article-title":"Molecular engineering and design of therapeutic antibodies","volume":"20","author":"Presta","year":"2008","journal-title":"Curr. Opin. Immunol."},{"issue":"5\u20136","key":"10.1016\/j.intimp.2020.106760_b0205","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.addr.2006.01.026","article-title":"Engineering of therapeutic antibodies to minimize immunogenicity and optimize function","volume":"58","author":"Presta","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"29","key":"10.1016\/j.intimp.2020.106760_b0210","doi-asserted-by":"crossref","first-page":"12123","DOI":"10.1073\/pnas.0701000104","article-title":"Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies","volume":"104","author":"Zhu","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"5","key":"10.1016\/j.intimp.2020.106760_b0215","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1074\/jbc.C300520200","article-title":"A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2","volume":"279","author":"Wong","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.intimp.2020.106760_b0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030237","article-title":"Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants","volume":"3","author":"Ter Meulen","year":"2006","journal-title":"PLoS Med."},{"issue":"23","key":"10.1016\/j.intimp.2020.106760_b0225","doi-asserted-by":"crossref","first-page":"15829","DOI":"10.1074\/jbc.M600697200","article-title":"Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody","volume":"281","author":"Prabakaran","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.intimp.2020.106760_b0230","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1099\/jmm.0.000744","article-title":"Identification and characterization of a novel single-chain variable fragment (scFv) antibody against Neisseria meningitidis factor H-binding protein (fHbp)","volume":"67","author":"Yarian","year":"2018","journal-title":"J. Med. Microbiol."},{"issue":"8","key":"10.1016\/j.intimp.2020.106760_b0235","doi-asserted-by":"crossref","first-page":"1750069","DOI":"10.1142\/S0219633617500699","article-title":"In silico evaluation of the interactions among two selected single chain variable fragments (scFvs) and ESAT-6 antigen of Mycobacterium tuberculosis","volume":"16","author":"Mojgan Bandehpour","year":"2017","journal-title":"J. Theor. Comput. Chem."},{"key":"10.1016\/j.intimp.2020.106760_b0240","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ijbiomac.2020.01.039","article-title":"Diagnostic and therapeutic potential of shark variable new antigen receptor (VNAR) single domain antibody","volume":"147","author":"Cheong","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"issue":"1","key":"10.1016\/j.intimp.2020.106760_b0245","first-page":"1","article-title":"Construction and next-generation sequencing analysis of a large phage-displayed VNAR single-domain antibody library from six naive nurse sharks","volume":"2","author":"Feng","year":"2019","journal-title":"Antib Ther."},{"issue":"5","key":"10.1016\/j.intimp.2020.106760_b0250","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00219-16","article-title":"Development of a nanobody-based lateral flow immunoassay for detection of human norovirus","volume":"1","author":"Doerflinger","year":"2016","journal-title":"mSphere"},{"issue":"1","key":"10.1016\/j.intimp.2020.106760_b0255","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12934-017-0837-z","article-title":"Selection, characterization, and thermal stabilization of llama single domain antibodies towards Ebola virus glycoprotein","volume":"16","author":"Liu","year":"2017","journal-title":"Microb. Cell Fact."},{"issue":"1","key":"10.1016\/j.intimp.2020.106760_b0260","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1186\/1556-276X-9-528","article-title":"Combining magnetic nanoparticle with biotinylated nanobodies for rapid and sensitive detection of influenza H3N2","volume":"9","author":"Zhu","year":"2014","journal-title":"Nanoscale Res. Lett."},{"issue":"2","key":"10.1016\/j.intimp.2020.106760_b0265","first-page":"52","article-title":"Selection, expression and purification of single-chain Fv antibodies against non-structural proteins of GB virus C","volume":"7","author":"Agne Valinciute-Jankauskiene","year":"2015","journal-title":"J Antivir Antiretrovir."},{"issue":"10","key":"10.1016\/j.intimp.2020.106760_b0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135859","article-title":"Antibody derived peptides for detection of Ebola virus glycoprotein","volume":"10","author":"Rodriguez-Martinez","year":"2015","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.intimp.2020.106760_b0275","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21020492","article-title":"Expression, purification, and characterization of anti-Zika virus envelope protein: polyclonal and chicken-derived single chain variable fragment antibodies","volume":"21","author":"Mwale","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2020.106760_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.100867","article-title":"Engineering cellular biosensors with customizable antiviral responses targeting hepatitis B virus","volume":"23","author":"Matsunaga","year":"2020","journal-title":"iScience"},{"issue":"5","key":"10.1016\/j.intimp.2020.106760_b0285","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1080\/13102818.2017.1348256","article-title":"Cloning of anti-HBsAg single-chain variable fragments from hybridoma cells for one-step Elisa","volume":"31","author":"Berrin Erdaga","year":"2017","journal-title":"Biotechnol. Biotechnol. Equip."},{"issue":"6","key":"10.1016\/j.intimp.2020.106760_b0290","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1128\/CVI.00310-06","article-title":"Rapid detection of hepatitis B virus surface antigen by an agglutination assay mediated by a bispecific diabody against both human erythrocytes and hepatitis B virus surface antigen","volume":"14","author":"Chen","year":"2007","journal-title":"Clin. Vaccine Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2020.106760_b0295","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41590-017-0007-9","article-title":"Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic","volume":"19","author":"Graham","year":"2018","journal-title":"Nat. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2020.106760_b0300","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1517\/14712598.2.7.763","article-title":"Palivizumab in the prevention of respiratory syncytial virus disease","volume":"2","author":"Krilov","year":"2002","journal-title":"Expert Opin. Biol. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2020.106760_b0305","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1358\/dot.2019.55.1.2895651","article-title":"Ibalizumab for the treatment of multidrug-resistant HIV-1 infection","volume":"55","author":"Rizza","year":"2019","journal-title":"Drugs Today (Barcelona, Spain: 1998)"},{"issue":"1","key":"10.1016\/j.intimp.2020.106760_b0310","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40121-018-0188-z","article-title":"Past, present and future approaches to the prevention and treatment of respiratory syncytial virus infection in children","volume":"7","author":"Sim\u00f5es","year":"2018","journal-title":"Infect. Diseases Therapy"},{"issue":"9","key":"10.1016\/j.intimp.2020.106760_b0315","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/INF.0000000000001916","article-title":"Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion F-targeting monoclonal antibody administered as a single dose to healthy preterm infants","volume":"37","author":"Domachowske","year":"2018","journal-title":"Pediatr. Infect. Dis. J."},{"issue":"2","key":"10.1016\/j.intimp.2020.106760_b0320","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.antiviral.2004.06.012","volume":"64","author":"Borucki","year":"2004","journal-title":"Antiviral Res."},{"issue":"4","key":"10.1016\/j.intimp.2020.106760_b0325","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/COH.0000000000000479","article-title":"The return of PRO 140, a CCR5-directed mAb","volume":"13","author":"Thompson","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"24","key":"10.1016\/j.intimp.2020.106760_b0330","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01603-17","article-title":"In vitro neutralization is not predictive of prophylactic efficacy of broadly neutralizing monoclonal antibodies CR6261 and CR9114 against lethal H2 influenza virus challenge in mice","volume":"91","author":"Sutton","year":"2017","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.intimp.2020.106760_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2019.02.003","article-title":"Human memory B cells harbor diverse cross-neutralizing antibodies against BK and JC polyomaviruses","volume":"50","author":"Lindner","year":"2019","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.intimp.2020.106760_b0340","doi-asserted-by":"crossref","first-page":"396","DOI":"10.2174\/0929867324666170817152554","article-title":"Antibody fragments as potential biopharmaceuticals for cancer therapy: success and limitations","volume":"26","author":"Kholodenko","year":"2019","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.intimp.2020.106760_b0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-017-0019-3","article-title":"Antibody therapies for the prevention and treatment of viral infections","volume":"2","author":"Salazar","year":"2017","journal-title":"npj Vaccines"},{"key":"10.1016\/j.intimp.2020.106760_b0350","series-title":"Delivery of ALX-0171 by Inhalation Greatly Reduces Respiratory Syncytial Virus Disease in Newborn Lambs. MAbs","year":"2018"},{"issue":"1","key":"10.1016\/j.intimp.2020.106760_b0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-08273-7","article-title":"Selection of nanobodies with broad neutralizing potential against primary HIV-1 strains using soluble subtype C gp140 envelope trimers","volume":"7","author":"Koch","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2020.106760_b0360","series-title":"Nanobodies and Their In Vivo Applications. Advanced Biosensors for Health Care Applications","first-page":"263","author":"Singh","year":"2019"},{"key":"10.1016\/j.intimp.2020.106760_b0365","doi-asserted-by":"crossref","DOI":"10.2217\/fvl-2019-0167","article-title":"Nanobodies: a new approach for the diagnosis and treatment of viral infectious diseases","author":"Sroga","year":"2020","journal-title":"Future Virol."},{"issue":"6","key":"10.1016\/j.intimp.2020.106760_b0370","doi-asserted-by":"crossref","first-page":"e01569","DOI":"10.1128\/mBio.01569-16","article-title":"The antiviral mechanism of an influenza A virus nucleoprotein-specific single-domain antibody fragment","volume":"7","author":"Hanke","year":"2016","journal-title":"MBio"},{"issue":"1","key":"10.1016\/j.intimp.2020.106760_b0375","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3390\/v11010058","article-title":"Single chain fragment variable (scFv) antibodies targeting the spike protein of porcine epidemic diarrhea virus provide protection against viral infection in piglets","volume":"11","author":"Zhang","year":"2019","journal-title":"Viruses"},{"issue":"33","key":"10.1016\/j.intimp.2020.106760_b0380","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1016\/j.vaccine.2018.02.057","article-title":"In vitro and in vivo evaluation of a single chain antibody fragment generated in planta with potent rabies neutralisation activity","volume":"37","author":"Phoolcharoen","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2020.106760_b0385","series-title":"Generation and Characterization of Protective Antibodies to Marburg Virus. MAbs","year":"2017"},{"issue":"2","key":"10.1016\/j.intimp.2020.106760_b0390","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01533-19","article-title":"Neutralization breadth and potency of single-chain variable fragments derived from broadly neutralizing antibodies targeting multiple epitopes on the HIV-1 envelope","volume":"94","author":"van Dorsten","year":"2020","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.intimp.2020.106760_b0395","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1134\/S0026893317060085","article-title":"Antibody-based drugs and other recombinant proteins for diagnostics and therapy of viral infections, autoimmune diseases and cancer","volume":"51","author":"Kuprash","year":"2017","journal-title":"Mole. Biol."},{"issue":"2","key":"10.1016\/j.intimp.2020.106760_b0400","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/hep.24692","article-title":"A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo","volume":"55","author":"Meuleman","year":"2012","journal-title":"Hepatology"},{"issue":"7706","key":"10.1016\/j.intimp.2020.106760_b0405","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/s41586-018-0121-3","article-title":"Mxra8 is a receptor for multiple arthritogenic alphaviruses","volume":"557","author":"Zhang","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2020.106760_b0410","article-title":"Biophysical characterization and single-chain Fv construction of a neutralizing antibody to measles virus","volume":"287","author":"Tadokoro","year":"2019","journal-title":"The FEBS J."},{"key":"10.1016\/j.intimp.2020.106760_b0415","article-title":"Targeting the HIV-1 spike and coreceptor with Bi- and trispecific antibodies for single-component broad inhibition of entry","author":"Khan","year":"20189218","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.intimp.2020.106760_b0420","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/QAI.0000000000001119","article-title":"Distinct HIV-1 neutralization potency profiles of ibalizumab-based bispecific antibodies","volume":"73","author":"Song","year":"2016","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.intimp.2020.106760_b0425","article-title":"Haiming effective treatment of severe COVID-19 patients with Tocilizumab","author":"Xu","year":"2020","journal-title":"ChinaXiv"},{"key":"10.1016\/j.intimp.2020.106760_b0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.03.300","article-title":"Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report","author":"Michot","year":"2020","journal-title":"Ann. Oncol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920316313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920316313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:54:15Z","timestamp":1769028855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576920316313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":86,"alternative-id":["S1567576920316313"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106760","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An update on antiviral antibody-based biopharmaceuticals","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106760","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106760"}}